Entrada Therapeutics, Inc. (TRDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TRDA Stock Price Chart Interactive Chart >
TRDA Price/Volume Stats
| Current price | $12.06 | 52-week high | $24.38 |
| Prev. close | $11.67 | 52-week low | $5.12 |
| Day low | $11.79 | Volume | 17,700 |
| Day high | $12.47 | Avg. volume | 43,317 |
| 50-day MA | $15.62 | Dividend yield | N/A |
| 200-day MA | $12.87 | Market Cap | 378.76M |
Entrada Therapeutics, Inc. (TRDA) Company Bio
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest TRDA News From Around the Web
Below are the latest news stories about ENTRADA THERAPEUTICS INC that investors may wish to consider to help them evaluate TRDA as an investment opportunity.
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping AmenableENTR-601-45 Expands Entrada’s Commitment to the Duchenne Community by Advancing a Potential Treatment for People Living with Duchenne Who are Exon 45 Skipping Amenable Figure 1 ENTR-601-45 showed robust exon skipping and dystrophin production in vitro in patient-derived skeletal and cardiac muscle cells Figure 2 A single IV dose of ENTR-601-45 showed high levels of exon skipping in hDMD mouse skeletal and heart muscle after one week BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDANEW YORK, Dec. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980…. |
Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & MorePipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week. |
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On TuesdayU.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. Entrada Therapeutics Inc (NASDAQ: TRDA ) shares dipped 33.5% to $13.22 after the company said it received a clinical hold notice from the FDA regarding its Investigational New Drug Application for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy. Arcus Biosciences, Inc. (NYSE: RCUS ) declined 28.1% to $21.92. Gilead Sciences and Arcus Biosciences announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth … Full story available on Benzinga.com |
Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving PremarketGainers IceCure Medical Ltd (NASDAQ: ICCM ) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery. Exicure, Inc. (NASDAQ: XCUR ) shares rose 46% to $1.08 in pre-market trading. Exicure 10% owner CBI USA, Inc. acquired a total of 3,400,000 shares at an average price of $1.60. Verona Pharma plc (NASDAQ: VRNA ) rose 39.3% to $18.80 in pre-market trading after the company reported positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. Otonomy, Inc (NASDAQ: OTIC ) rose 28.6% to $0.1475 in pre-market trading after the company issued ... |
TRDA Price Returns
| 1-mo | -10.93% |
| 3-mo | -46.75% |
| 6-mo | -5.78% |
| 1-year | 44.09% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -10.80% |
| 2022 | -21.03% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...